Specific Na+/K+-ATPase inhibitor. Less active than ouabain (Prod. No. ALX-350-066).
Product Specification
| Alternative Name: | 5β,20(22)-Bufadienolide-14,15β-epoxy-3β,5α,16β-triol 16-acetate, 14,15β-Epoxy-3β,5α,16β-trihydroxy-5β,20(22)-bufadienolide 16-acetate |
| |
| Formula: | C26H34O7 |
| |
| MW: | 458.6 |
| |
| CAS: | 1108-68-5 |
| |
| MI: | 14: 2307 |
| |
| RTECS: | EI2991000 |
| |
| Purity: | ≥97% (HPLC) |
| |
| Appearance: | White to off-white solid. |
| |
| Solubility: | Soluble in chloroform. |
| |
| Shipping: | Shipped on Blue Ice |
| |
| Long Term Storage: | +4°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Cardiotonic steroids differentially affect intracellular Na+ and [Na+]i/[K+]i-independent signaling in C7-MDCK cells: O.A. Akimova, et al.; J. Biol. Chem.
280, 832 (2005),
Abstract;
Simultaneous determination of four bufadienolides in human liver by high-performance liquid chromatography: Z. Wang, et al.; Biomed. Chromatogr.
18, 318 (2004),
Abstract;
Neutralization of cardiac toxins oleandrin, oleandrigenin, bufalin, and cinobufotalin by digibind: monitoring the effect by measuring free digitoxin concentrations: A. Dasgupta & L. Emerson ; Life Sci.
63, 781 (1998),
Abstract;
Actions of bufalin and cinobufotalin, two bufadienolides respectively more active and less active than ouabain, on ouabain binding and 86Rb uptake by human erythrocytes: A.A. Brownlee, et al.; Clin. Sci. (Lond.)
78, 169 (1990),
Abstract;
Related Products
